Actively Recruiting
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
Led by Assiut University · Updated on 2025-08-05
80
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.
CONDITIONS
Official Title
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 65 years
- American Society of Anesthesiologists (ASA) class I-II
- Diagnosed with sepsis with a qSOFA score of 2 or higher
- Require ICU admission
You will not qualify if you...
- Chronic renal failure
- Liver cirrhosis
- Bleeding disorders or current anticoagulant therapy
- Pregnancy or breastfeeding
- Impaired color vision
- Severe vascular ischemia, history of venous thrombosis or pulmonary embolism
- Long-term treatment with acetylsalicylic acid or NSAIDs not stopped before ICU admission
- Allergy to tranexamic acid (TXA)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Assiut university hospital
Asyut, Egypt
Actively Recruiting
Research Team
O
Omar Soliman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here